Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MCRB Seres Therapeutics	$7.50 -6.1%	$8.43	$6.53 ▼ $30.60	$65.49M	2.62	136,032 shs	36,986 shs
MNOV MediciNova	$1.33 -3.6%	$1.43	$1.12 ▼ $2.55	$65.23M	0.42	37,627 shs	3,017 shs
PIRS Pieris Pharmaceuticals	$13.60	$15.17	$6.20 ▼ $18.68	$17.95M	0.61	78,413 shs	51,728 shs
STRO Sutro Biopharma	$0.80 -1.5%	$0.84	$0.52 ▼ $5.17	$67.49M	1.7	1.11 million shs	700,274 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MCRB Seres Therapeutics	-6.13%	-8.87%	+10.78%	-45.64%	-49.70%
MNOV MediciNova	-3.62%	-5.67%	-2.92%	-14.19%	-1.48%
PIRS Pieris Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+35.05%
STRO Sutro Biopharma	-1.50%	-5.77%	+9.02%	-1.36%	-79.51%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MCRB Seres Therapeutics	3.5921 of 5 stars	2.9	3.0	0.0	4.6	2.7	0.8	0.0
MNOV MediciNova	2.1029 of 5 stars	3.5	3.0	0.0	0.0	2.7	0.8	0.0
PIRS Pieris Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
STRO Sutro Biopharma	4.2166 of 5 stars	3.1	4.0	0.0	4.7	2.7	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MCRB Seres Therapeutics	1.75	Reduce	$73.67	882.22% Upside
MNOV MediciNova	3.00	Buy	$9.00	576.69% Upside
PIRS Pieris Pharmaceuticals	0.00	N/A	N/A	N/A
STRO Sutro Biopharma	2.13	Hold	$6.11	665.15% Upside

Current Analyst Ratings Breakdown

Latest PIRS, MCRB, STRO, and MNOV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/19/2025	STRO Sutro Biopharma	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underperform ➝ Underperform	$1.00 ➝ $0.80
5/8/2025	MCRB Seres Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$1.25 ➝ $6.00
4/29/2025	STRO Sutro Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$2.00 ➝ $2.00
4/9/2025	MNOV MediciNova	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
3/20/2025	MCRB Seres Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
3/17/2025	STRO Sutro Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$12.00 ➝ $2.00
3/14/2025	STRO Sutro Biopharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$2.00
3/14/2025	MCRB Seres Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sell ➝ Sell	$20.00 ➝ $15.00
3/14/2025	MNOV MediciNova	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
3/14/2025	STRO Sutro Biopharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
3/14/2025	STRO Sutro Biopharma	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform

(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MCRB Seres Therapeutics	$126.33M	0.52	N/A	N/A	($0.35) per share	-21.43
MNOV MediciNova	$1M	65.23	N/A	N/A	$1.07 per share	1.24
PIRS Pieris Pharmaceuticals	$42.81M	0.42	N/A	N/A	$21.66 per share	0.63
STRO Sutro Biopharma	$66.43M	1.02	N/A	N/A	$2.45 per share	0.33

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MCRB Seres Therapeutics	-$113.72M	-$4.60	N/A	N/A	N/A	N/A	N/A	-55.08%	8/12/2025 (Estimated)
MNOV MediciNova	-$8.56M	-$0.23	N/A	N/A	N/A	N/A	-19.66%	-18.63%	8/6/2025 (Estimated)
PIRS Pieris Pharmaceuticals	-$24.54M	-$12.10	N/A	∞	N/A	-39.71%	-80.93%	-59.55%	N/A
STRO Sutro Biopharma	-$106.79M	-$2.98	N/A	N/A	N/A	-77.01%	-101.89%	-28.69%	8/12/2025 (Estimated)

Latest PIRS, MCRB, STRO, and MNOV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	MNOV MediciNova	-$0.14	-$0.06	+$0.08	-$0.06	N/A	N/A
5/8/2025	Q1 2025	STRO Sutro Biopharma	-$0.63	-$0.91	-$0.28	-$0.91	$11.61 million	$17.40 million
5/7/2025	Q1 2025	MCRB Seres Therapeutics	-$0.67	-$2.24	-$1.57	$3.75	$10.00 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MCRB Seres Therapeutics	N/A	N/A	N/A	N/A	N/A
MNOV MediciNova	N/A	N/A	N/A	N/A	N/A
PIRS Pieris Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
STRO Sutro Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MCRB Seres Therapeutics	N/A	1.12	1.12
MNOV MediciNova	N/A	13.88	16.66
PIRS Pieris Pharmaceuticals	N/A	4.82	4.82
STRO Sutro Biopharma	N/A	3.09	3.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MCRB Seres Therapeutics	59.34%
MNOV MediciNova	9.90%
PIRS Pieris Pharmaceuticals	40.11%
STRO Sutro Biopharma	96.99%

Insider Ownership

Company	Insider Ownership
MCRB Seres Therapeutics	4.70%
MNOV MediciNova	13.60%
PIRS Pieris Pharmaceuticals	6.39%
STRO Sutro Biopharma	3.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MCRB Seres Therapeutics	330	8.73 million	162.03 million	Optionable
MNOV MediciNova	10	49.05 million	41.74 million	Optionable
PIRS Pieris Pharmaceuticals	140	1.32 million	1.24 million	Optionable
STRO Sutro Biopharma	240	84.46 million	77.59 million	Optionable

PIRS, MCRB, STRO, and MNOV Headlines

Recent News About These Companies

Sutro Biopharma, Inc. (NASDAQ:STRO) Shares Sold by Millennium Management LLC

June 7, 2025 | marketbeat.com

Sutro Biopharma, Inc. (NASDAQ:STRO) Short Interest Update

June 3, 2025 | marketbeat.com

Sutro Biopharma Appoints Greg Chow as Chief Financial Officer

June 2, 2025 | finance.yahoo.com

Sutro Biopharma, Inc. (NASDAQ:STRO) Given Consensus Rating of "Hold" by Brokerages

May 24, 2025 | marketbeat.com

Point72 Asset Management L.P. Has $4.04 Million Stock Holdings in Sutro Biopharma, Inc. (NASDAQ:STRO)

May 22, 2025 | marketbeat.com

2,570,000 Shares in Sutro Biopharma, Inc. (NASDAQ:STRO) Purchased by Vestal Point Capital LP

May 21, 2025 | marketbeat.com

Suvretta Capital Management LLC Grows Position in Sutro Biopharma, Inc. (NASDAQ:STRO)

May 19, 2025 | marketbeat.com

MPM Bioimpact LLC Has $3.98 Million Position in Sutro Biopharma, Inc. (NASDAQ:STRO)

May 16, 2025 | marketbeat.com

Sutro Biopharma (NASDAQ:STRO) Releases Earnings Results, Misses Expectations By $0.28 EPS

May 14, 2025 | marketbeat.com

Sutro Biopharma, Inc.: Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights

May 9, 2025 | finanznachrichten.de

Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates

May 8, 2025 | zacks.com

Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights

May 8, 2025 | globenewswire.com

Sutro Biopharma to Participate in Upcoming Investor Conferences

May 1, 2025 | globenewswire.com

Why Sutro Biopharma, Inc.’s (STRO) Stock Is Down 21.92%

April 26, 2025 | aaii.com

Why Sutro Biopharma, Inc.’s (STRO) Stock Is Down 10.88%

April 1, 2025 | aaii.com

Why Sutro Biopharma, Inc.’s (STRO) Stock Is Up 15.10%

March 18, 2025 | aaii.com

Sutro Biopharma downgraded to Neutral from Buy at H.C. Wainwright

March 17, 2025 | markets.businessinsider.com

HC Wainwright & Co. Downgrades Sutro Biopharma (STRO)

March 17, 2025 | msn.com

Sutro Biopharma presents expanded data from REFRalphaME-01 trial

March 17, 2025 | markets.businessinsider.com

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRaME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

March 15, 2025 | tmcnet.com

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRaME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

March 15, 2025 | tmcnet.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Top-Rated Energy Companies Staging Strong Recoveries
By Nathan Reiff | June 2, 2025
View 3 Top-Rated Energy Companies Staging Strong Recoveries
If the U.S.-China Trade Reset Holds, These 3 Stocks Could Fly
By Chris Markoch | May 16, 2025
View If the U.S.-China Trade Reset Holds, These 3 Stocks Could Fly
Archer Rebuts Short Seller, Points to Strong Q1 & Global Momentum
By Jeffrey Neal Johnson | May 22, 2025
View Archer Rebuts Short Seller, Points to Strong Q1 & Global Momentum
3 Top Dividend Stocks Analysts Are Bullish on Right Now
By Chris Markoch | June 6, 2025
View 3 Top Dividend Stocks Analysts Are Bullish on Right Now
After Earnings Beats, These 3 Stocks Are on Analysts’ Radars
By Leo Miller | May 20, 2025
View After Earnings Beats, These 3 Stocks Are on Analysts’ Radars

PIRS, MCRB, STRO, and MNOV Company Descriptions

Seres Therapeutics NASDAQ:MCRB

$7.50 -0.49 (-6.13%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$7.61 +0.11 (+1.48%)

As of 06/13/2025 06:29 PM Eastern

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

MediciNova NASDAQ:MNOV

$1.33 -0.05 (-3.62%)

Closing price 06/13/2025 03:58 PM Eastern

Extended Trading

$1.34 +0.01 (+0.75%)

As of 06/13/2025 04:04 PM Eastern

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

Pieris Pharmaceuticals NASDAQ:PIRS

Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.

Sutro Biopharma NASDAQ:STRO

$0.80 -0.01 (-1.50%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$0.81 +0.01 (+1.49%)

As of 06/13/2025 07:00 PM Eastern

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time